Numerous tumour-expressed growth factors, endothelial markers, and cytokines attract and activate osteoclasts, which in turn disrupt the bone balance through overstimulation and discharge of bone-derived growth factors (Figure 2). pathways have shown promising clinical application and are being investigated in clinical trials. == 1. Introduction == The five-year survival rate for prostate malignancy is extremely high when confined to the prostate, but in the presence of metastatic disease it is reduced to 33% [1]. In Australia, prostate malignancy contributes to almost 5% of all registered male Brivanib (BMS-540215) deaths [2] of which more than 80% will have developed spinal metastases during the course of their disease [35]. Once malignancy metastasizes to bone and the vertebral column, patients often experience intractable pain and neurological deficit due to pathological fractures, spinal instability, and metastatic epidural spinal cord compression. The neurological sequelae include sensory disturbance, motor weakness, paralysis, and incontinence, leading to decreased function, failure to ambulate and impaired quality of life [5]. Treatment options include radiotherapy, hormonal therapy, chemotherapeutic brokers such as docetaxel, cabazitaxel, sipuleucel-T and abiraterone acetate, and decompression and stabilization surgery [6,7]. These modalities may be able to lengthen survival rates but are all predominantly palliative, with median survival time limited from one to two years from the onset of metastases [5,6]. Despite the clinical implication and high incidence of spinal metastasis, the molecular mechanisms behind prostate malignancy metastasis to bone and the Brivanib (BMS-540215) spine are not well comprehended. Vascular endothelial growth factor (VEGF) is well known Brivanib (BMS-540215) to be potent stimulator of angiogenesis in both physiological and pathological conditions and is highly expressed in most solid tumours, including prostate malignancy. This review discusses the role of VEGF in tumour angiogenesis and bone destruction in metastatic prostate malignancy to the spine. == 2. VEGF and Its Receptors == VEGF is usually a ligand of the VEGF tyrosine kinase receptor superfamily and includes VEGF-A, -B, -C and -D, with splice variants of VEGF-A resulting in several different isoforms [8,9]. The Rtn4r VEGF family ligands bind to tyrosine kinase receptors VEGFR1, VEGFR2, and VEGFR3 (Physique 1), each receptor made up of an extracellular domain name of approximately 750 amino acid residues, arranged within seven immunoglobulin-like folds [10]. Additionally, heparin sulphate proteoglycans (HSPGs) as well as neuropilins (NRP-1 and NRP-2) can act as coreceptors for VEGF and promote VEGFR activation [11,12]. Each VEGF family member binds with differential affinity for their receptors; for example, VEGFR2 is usually primarily activated by VEGF-A and VEGFR3 is only activated by VEGF-C and -D. Upon specific VEGF binding, the three VEGF receptors induce receptor dimerization and autophosphorylation leading to downstream signaling via a number of secondary messengers including several protein kinases and phosphatases that support a proangiogenic phenotype [1012]. Important pathways include the phosphoinositide 3-kinase/Protein Kinase B/NF-B pathway that promotes cell survival, the mitogen-activated protein kinase (MAPK) pathway that promotes cell proliferation, and the Ras/extracellular signal-regulated kinase (ERK) pathway that promotes cell proliferation, survival, differentiation, migration, and angiogenesis. Through these signaling pathways each of the Brivanib (BMS-540215) VEGF family provides different actions, with VEGF-A activation of VEGFR2 representing the major mediator of angiogenesis induction [1315]. == Physique 1. == VEGF receptor binding. The five mammalian vascular endothelial growth factors (VEGF-A-D) bind to the receptor tyrosine kinases, VEGF receptor (VEGFR1-3 and co-receptors HSPG, NRP-1 and NRP-2). VEGFR-binding prospects to the formation of homodimers and/or heterodimers. Proteolytic cleavage enables VEGF-C and -D to bind VEGFR-2 forming a homodimer. The binding and activation of VEGFR-2 lead to downstream signaling of the PI3 K, MAPK, and Ras pathways which promote cell survival, proliferation, differentiation, migration, and angiogenesis. There are numerous factors that influence and regulate the VEGF/VEGFR pathway, including local environmental hypoxia and various hormones, growth factors, and cytokines. Hormones such as androgens upregulate stromal cell and malignant cell VEGF production and angiogenesis, enhancing prostate malignancy growth [1618]. As such, hormone withdrawal has been shown to inhibit VEGF expression as well as angiogenesis in prostate malignancy patients while inducing apoptosis in.